REMUS Q4 FY26 results at a glance
REMUS PHARMACEUTICALS L Q4 FY26 key results metrics| Quarter | Q4 FY26 |
|---|
| Quarter ended | 31 Mar 2026 |
|---|
| Revenue | ₹453 cr |
|---|
| Revenue YoY | +30.4% |
|---|
| Operating profit | ₹28.3 cr |
|---|
| Operating margin | 6.2% |
|---|
| Net profit | ₹19.49 cr |
|---|
| Net profit YoY | +21.7% |
|---|
| Net profit QoQ | +21.7% |
|---|
| Net margin | 4.3% |
|---|
| Basic EPS | ₹20.86 |
|---|
| TTM revenue | — |
|---|
| TTM net profit | — |
|---|
| TTM net margin | — |
|---|
REMUS Q4 FY26 results: what the numbers say
REMUS PHARMACEUTICALS L (REMUS) has reported its Q4 FY26 results for the quarter ended 2026-03-31. The company posted revenue of ₹453 cr and a net profit of ₹19.49 cr, translating into earnings per share of ₹20.86.
Compared with the same quarter a year earlier, revenue grew strongly by +30.4% and net profit grew strongly by +21.7%. Profit trailing revenue growth suggests costs, interest or tax absorbed part of the topline gain.
Operating profit for the quarter stood at ₹28.3 cr, an operating margin of 6.2% versus 6.7% a year ago — a contraction of 0.5 percentage points.
REMUS quarter-wise results table
Net profit
₹19.49 cr
+21.7% YoY
Operating profit
₹28.3 cr
+21.1% YoY
REMUS PHARMACEUTICALS L (REMUS) quarter-wise results — revenue, operating profit, net profit, margins, EPS and growth| Quarter | Revenue | Operating profit | Net profit | OPM | Net margin | EPS | Profit YoY | Profit QoQ |
|---|
| Q4 FY262026-03-31 | ₹453 cr | ₹28.3 cr | ₹19.49 cr | 6.2% | 4.3% | ₹20.86 | +21.7% | +21.7% |
| Q4 FY252025-03-31 | ₹348 cr | ₹23.36 cr | ₹16.01 cr | 6.7% | 4.6% | ₹17.46 | — | — |
Consolidated figures as reported to the exchanges, shown in ₹ crore. OPM = operating profit margin. Updated automatically whenever a new quarter is filed.
REMUS quarterly income statement
Line-item results for the last six quarters as filed — sales, expenses, operating profit, interest, tax and profit after tax in ₹ crore.
REMUS PHARMACEUTICALS L quarterly income statement| Particulars | Q4 FY262026-03-31 | Q4 FY252025-03-31 |
|---|
| Revenue / Sales | ₹453 cr | ₹348 cr |
|---|
| Total expenses | ₹425 cr | ₹324 cr |
|---|
| Gross profit | ₹60.76 cr | ₹46.35 cr |
|---|
| Operating profit (EBIT) | ₹28.3 cr | ₹23.36 cr |
|---|
| Operating margin | 6.2% | 6.7% |
|---|
| Interest cost | ₹0.82 cr | ₹0.64 cr |
|---|
| Profit before tax | ₹31.26 cr | ₹25.35 cr |
|---|
| Tax expense | ₹6.68 cr | ₹4.78 cr |
|---|
| Effective tax rate | 21.4% | 18.9% |
|---|
| Net profit (PAT) | ₹19.49 cr | ₹16.01 cr |
|---|
| Net profit margin | 4.3% | 4.6% |
|---|
| Basic EPS | ₹20.86 | ₹17.46 |
|---|
| Diluted EPS | ₹20.86 | ₹17.46 |
|---|
REMUS results growth — YoY and QoQ
Quarterly growth rates, year on year and quarter on quarter| Growth | Q4 FY26 | Q4 FY25 |
|---|
| Revenue YoY | +30.4% | — |
|---|
| Revenue QoQ | +30.4% | — |
|---|
| Operating profit YoY | +21.1% | — |
|---|
| Operating profit QoQ | +21.1% | — |
|---|
| Net profit YoY | +21.7% | — |
|---|
| Net profit QoQ | +21.7% | — |
|---|
| EPS YoY | +19.5% | — |
|---|
| EPS QoQ | +19.5% | — |
|---|
REMUS annual results history
Full-year performance for REMUS PHARMACEUTICALS L, useful for reading each quarter in context.
REMUS PHARMACEUTICALS L annual income statement| Particulars | FY262026-03-31 | FY252025-03-31 | FY242024-03-31 | FY222022-03-31 |
|---|
| Revenue / Sales | ₹839 cr | ₹610 cr | ₹210 cr | ₹24.72 cr |
|---|
| Total expenses | ₹785 cr | ₹566 cr | ₹182 cr | ₹20.63 cr |
|---|
| Gross profit | ₹96.38 cr | ₹77.43 cr | ₹46.9 cr | ₹12.43 cr |
|---|
| Operating profit (EBIT) | ₹53.92 cr | ₹44.61 cr | ₹27.83 cr | ₹4.09 cr |
|---|
| Operating margin | 6.4% | 7.3% | 13.2% | 16.5% |
|---|
| Interest cost | ₹1.47 cr | ₹1.46 cr | ₹0.5 cr | ₹0.08 cr |
|---|
| Profit before tax | ₹59.16 cr | ₹47.34 cr | ₹30.17 cr | ₹4.55 cr |
|---|
| Tax expense | ₹12.99 cr | ₹8.92 cr | ₹5.89 cr | ₹1.16 cr |
|---|
| Effective tax rate | 22.0% | 18.8% | 19.5% | 25.6% |
|---|
| Net profit (PAT) | ₹36.99 cr | ₹29.07 cr | ₹20.52 cr | ₹3.39 cr |
|---|
| Net profit margin | 4.4% | 4.8% | 9.8% | 13.7% |
|---|
| Basic EPS | — | ₹16.30 | ₹21.48 | ₹2.87 |
|---|
| Diluted EPS | — | ₹16.30 | ₹21.48 | ₹2.87 |
|---|
Revenue trend and demand read-through
Topline for Q4 FY26 came in at ₹453 cr against ₹348 cr in Q4 FY25, and ₹348 cr in the preceding Q4 FY25 quarter.
On a sequential basis revenue grew +30.4%. Sequential moves are the quickest read on demand momentum because they strip out the base effect of a year-old quarter, though seasonality can distort a single quarter.
Total expenses for the quarter were ₹425 cr, or 93.8% of revenue, with operating profit grew +21.1% year on year.
Margins, tax and profitability
Net profit of ₹19.49 cr works out to a net margin of 4.3% compared with 4.6% in the year-ago quarter. Margin pressure of this kind usually reflects higher input costs, pricing competition, or a heavier interest and depreciation load.
Below the operating line, REMUS PHARMACEUTICALS L reported profit before tax of ₹31.26 cr, a tax charge of ₹6.68 cr (effective rate 21.4%), interest cost of ₹0.82 cr. Reading these together with operating profit shows how much of the quarter's earnings were driven by the core business versus financing and tax movements.
Sequentially, net profit moved from ₹16.01 cr in Q4 FY25 to ₹19.49 cr in Q4 FY26, a change of +21.7%.
Trailing twelve months and annual context
On a full-year basis, FY26 revenue was ₹839 cr with net profit of ₹36.99 cr and EPS of —, versus the prior year where revenue grew +37.4% and profit grew +27.2%.
What to watch in the next REMUS quarter
For the coming quarters the numbers worth tracking on this page are revenue momentum, the operating margin trend, the interest burden and whether EPS keeps pace with profit growth. A sustained run of year-on-year profit growth is what usually drives a re-rating rather than any single quarter.
REMUS PHARMACEUTICALS L has not yet intimated its next results date to the exchange. This page refreshes automatically from filings and the board-meeting calendar, so the tables above will reflect the next quarter as soon as it is reported.
All figures here are as reported to the exchanges and shown in ₹ crore, without adjustment. This is information and analysis, not investment advice.
REMUS results coverage
No results report published for REMUS yet — our desk covers each quarter within minutes of the filing.
REMUS quarterly results FAQs
What were REMUS PHARMACEUTICALS L (REMUS) Q4 FY26 results?
In Q4 FY26 (quarter ended 31 Mar 2026), REMUS PHARMACEUTICALS L reported revenue of ₹453 cr and net profit of ₹19.49 cr, a change of +21.7% year on year on +30.4% revenue growth. EPS stood at ₹20.86.
What is REMUS profit margin in Q4 FY26?
REMUS PHARMACEUTICALS L posted a net profit margin of 4.3% and an operating margin of 6.2% in Q4 FY26. On a trailing twelve-month basis, revenue is — and net profit —.
Did REMUS results beat the previous quarter?
REMUS PHARMACEUTICALS L net profit changed +21.7% quarter on quarter, from ₹16.01 cr in Q4 FY25 to ₹19.49 cr in Q4 FY26.
When are REMUS PHARMACEUTICALS L (REMUS) quarterly results?
REMUS PHARMACEUTICALS L has not yet intimated its next results date to the exchange. This page updates automatically from the exchange board-meeting calendar.
Where can I see REMUS latest quarterly results?
Results coverage for REMUS will appear here as soon as the company reports. Meanwhile you can track live price and technicals on the REMUS stock page.
What is REMUS PHARMACEUTICALS L annual revenue and profit?
For FY26, REMUS PHARMACEUTICALS L reported full-year revenue of ₹839 cr and net profit of ₹36.99 cr, with EPS of —.
How many quarterly results has REMUS declared recently?
Past results dates for REMUS will be listed here from the exchange calendar.
Results dates sourced from the exchange board-meeting calendar; reported figures from company filings, last refreshed 12 Sept 2026. For information only, not investment advice.
